La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Guobang Pharma Résultats passés
Passé contrôle des critères 2/6
Guobang Pharma has been growing earnings at an average annual rate of 4.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 10% per year. Guobang Pharma's return on equity is 8.1%, and it has net margins of 11.7%.
Informations clés
4.8%
Taux de croissance des bénéfices
1.0%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 10.0% |
| Rendement des fonds propres | 8.1% |
| Marge nette | 11.7% |
| Prochaine mise à jour des résultats | 30 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24
Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Ventilation des recettes et des dépenses
Comment Guobang Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 5,278 | 617 | 361 | 181 |
| 31 Dec 23 | 5,349 | 612 | 358 | 191 |
| 30 Sep 23 | 5,661 | 689 | 401 | 225 |
| 30 Jun 23 | 5,827 | 783 | 383 | 208 |
| 31 Mar 23 | 5,955 | 915 | 358 | 213 |
| 31 Dec 22 | 5,721 | 921 | 352 | 198 |
| 30 Sep 22 | 5,405 | 906 | 312 | 184 |
| 30 Jun 22 | 4,966 | 823 | 302 | 173 |
| 31 Mar 22 | 4,539 | 721 | 313 | 154 |
| 31 Dec 21 | 4,505 | 706 | 299 | 155 |
| 30 Sep 21 | 4,273 | 694 | 277 | 146 |
| 30 Jun 21 | 4,317 | 741 | 259 | 143 |
| 31 Mar 21 | 4,449 | 834 | 316 | 170 |
| 31 Dec 20 | 4,206 | 810 | 241 | 137 |
| 31 Dec 19 | 3,802 | 315 | 243 | 124 |
| 31 Dec 18 | 3,279 | 211 | 216 | 103 |
| 31 Dec 17 | 2,905 | 178 | 202 | 95 |
Des revenus de qualité: 605507 has high quality earnings.
Augmentation de la marge bénéficiaire: 605507's current net profit margins (11.7%) are lower than last year (15.4%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 605507's earnings have grown by 4.8% per year over the past 5 years.
Accélération de la croissance: 605507's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 605507 had negative earnings growth (-32.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 605507's Return on Equity (8.1%) is considered low.